Clinical trials: Sars-CoV2
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
COVID-19 Disease
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
This trial is composed of a randomized, double-blind, active controlled component (Part A) and an open-label, single-arm component (Part B) conducted in parallel.
- Trial name
- NCT05329220
- Testing
- ABNCoV2, Comirnaty
- Where
- 57 sites in United States, Belgium and 1 more
- Volunteers
- 4,205 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
SARS-CoV-2, Covid19
Protecting Our Community: COVID-19 Testing
The COVID-19 pandemic has disproportionately affected American Indian (AI) and Latino communities, and these groups also have increased risk of poor prognosis due to high rates of chronic disease such as diabetes, cardiovascular…
- Trial name
- NCT04866303
- Testing
- Home-based SARS-CoV-2 test kit
- Where
- 2 sites in United States
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Montana State University
Corona Virus Infection
Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
This is a phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion.
- Trial name
- COVID-19 (NCT04322682)
- Testing
- Colchicine
- Where
- 32 sites in United States, Brazil and 4 more
- Volunteers
- 4,506 people
- Sponsor
- Montreal Heart Institute
Coronavirus Infections
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and…
- Trial name
- COVID-19 (NCT04414618)
- Testing
- Opaganib
- Where
- 9 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- RedHill Biopharma Limited
COVID-19
A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.
This study aims to analyze the efficacy and safety of passive immunotherapy by administering an equine hyperimmune serum (INM005) against the SARS-CoV-2 receptor binding domain (RBD) to COVID-19 patients.
- Trial name
- NCT04494984
- Testing
- INM005
- Where
- 19 sites in Argentina
- Volunteers
- 243 people
- Sponsor
- Inmunova S.A.